NASDAQ:INKT

Mink Therapeutics Stock Insider Trading

etoro logo Buy INKT
*Your capital is at risk
$12.33
+0.0800 (+0.653%)
At Close: Jun 23, 2026

MiNK Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 69.57. In total, the insiders bought 761.33K and sold 24.23K INKT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
69.57
Buy 761.33K shares
Sell 24.23K shares
89% Buy Activity
Negligible or No Correlation
Sell Signal Low Confidence
Jun 04, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 69.57.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Mar 03, 2025
Buy
Common Stock
A-Award
Behner Peter
Director
Director 1 849
Value: $16.3K
Mar 03, 2025
Buy
Common Stock
A-Award
Corvese Brian
Director
Director 2 033
Value: $17.9K
Mar 03, 2025
Buy
Common Stock
A-Award
Wiinberg Ulf
Director
Director 1 593
Value: $14.0K
Mar 03, 2025
Buy
Common Stock
A-Award
Ryan Barbara
Director
Director 2 019
Value: $17.7K
Mar 03, 2025
Buy
Common Stock
A-Award
Corvese Brian
Director
Director 2 033
Value: $17.9K
Dec 01, 2024
Buy
Common Stock
A-Award
Kadlec Robert Peter
Director
Director 12 286
Value: $9K
Dec 01, 2024
Buy
Common Stock
A-Award
Kadlec Robert Peter
Director
Director 12 286
Value: $9K
Dec 01, 2024
Buy
Common Stock
A-Award
Corvese Brian
Director
Director 24 400
Value: $17.8K
Dec 01, 2024
Buy
Common Stock
A-Award
Behner Peter
Director
Director 20 987
Value: $15.3K
Dec 01, 2024
Buy
Common Stock
A-Award
Ryan Barbara
Director
Director 24 229
Value: $17.7K
Dec 01, 2024
Buy
Common Stock
A-Award
Wiinberg Ulf
Director
Director 20 476
Value: $14.9K
Dec 01, 2024
Buy
Common Stock
A-Award
Wiinberg Ulf
Director
Director 20 476
Value: $14.9K
Dec 01, 2024
Buy
Common Stock
A-Award
Behner Peter
Director
Director 20 987
Value: $15.3K
Dec 01, 2024
Buy
Common Stock
A-Award
Corvese Brian
Director
Director 24 400
Value: $17.8K
Dec 01, 2024
Buy
Common Stock
A-Award
Ryan Barbara
Director
Director 24 229
Value: $17.7K
Oct 30, 2024
Buy
Common Stock
J-Other
Kadlec Robert Peter
Insider
Other 0
Value: $0
Oct 30, 2024
Buy
Stock Option
A-Award
Kadlec Robert Peter
Director
Director 41 745
Value: $30.1K
Oct 30, 2024
Buy
Stock Option
A-Award
Kadlec Robert Peter
Director
Director 41 745
Value: $30.1K
Oct 30, 2024
Buy
Common Stock
J-Other
Kadlec Robert Peter
Insider
Other 0
Value: $0
Sep 03, 2024
Buy
Common Stock
A-Award
Ryan Barbara
Director
Director 21 649
Value: $17.8K
Sep 03, 2024
Buy
Common Stock
A-Award
Ryan Barbara
Director
Director 21 649
Value: $17.8K
Sep 03, 2024
Buy
Common Stock
A-Award
Wiinberg Ulf
Director
Director 18 295
Value: $15.0K
Sep 03, 2024
Buy
Common Stock
A-Award
Corvese Brian
Director
Director 21 802
Value: $17.9K
Sep 03, 2024
Buy
Common Stock
A-Award
Corvese Brian
Director
Director 21 802
Value: $17.9K
Sep 03, 2024
Buy
Common Stock
A-Award
Wiinberg Ulf
Director
Director 18 295
Value: $15.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT MINK THERAPEUTICS, INC.
MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was former...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.39% Jun 10
E
ETD
$20.67
4.79% Jun 05
EAT
$140.46
16.94% Jun 05
TPR
$140.47
7.16% Jun 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE